+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Activation of PPARgamma increases PTEN expression in pancreatic cancer cells

Biochemical and Biophysical Research Communications 301(1): 50-53

Activation of PPARgamma increases PTEN expression in pancreatic cancer cells

The PI3K pathway contributes to the invasive properties and apoptosis resistance that epitomize pancreatic cancers. PPARgamma is a ligand-activated transcription factor with anti-inflammatory and anti-tumor effects; the mechanisms of tumor suppression are unknown. The purpose of this study was to examine whether activation of PPARgamma can increase the expression of the tumor suppressor PTEN and inhibit PI3K activity. AsPC-1 human pancreatic cancer cells, transfected with a PPRE-luciferase construct, demonstrated increased luminescence following treatment with PPARgamma ligands, indicating the presence of functional PPARgamma protein. The selective PPARgamma ligand rosiglitazone increased PTEN expression in AsPC-1 cells; concurrent treatment with GW9662, which inhibits PPARgamma activation, prevented the increase in PTEN protein levels. Levels of phosphorylated Akt decreased as PTEN levels increased, indicating inhibition of PI3K activity. Taken together, our results suggest that activation of PPARgamma may represent a novel approach for the treatment of pancreatic cancer by increasing PTEN levels and inhibiting PI3K activity.

(PDF 0-2 workdays service: $29.90)

Accession: 010120055

PMID: 12535639

Related references

Effects of activated PPARgamma on the expression of PTEN gene in pancreatic cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24(7): 717-720, 2008

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 19(3): 546-551, 1999

Activation of Toll-like receptor 7 regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells. Molecular Medicine Reports 13(2): 1807-1812, 2016

Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clinical Cancer Research 14(7): 1997-2005, 2008

Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. International Journal of Cancer 118(10): 2390-2398, 2006

Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Surgery 134(2): 206-212, 2003

TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 298(2): G275-G282, 2010

PPARgamma and RXR synergistically inhibit the expression of cyclin D1 and suppress the growth of pancreatic cancer cells. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1111, April, 2000

TGF-b mediates PTEN suppression and cell motility through calcium-dependent PKC-a activation in pancreatic cancer cells. 2008

Activation of PPARgamma downregulates MET protooncogene expression and inhibits growth in renal cancer cells. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 505A, September, 2002